Cas:808769-54-2 (5ξ,18α)-3,22-Dihydroxyolean-12-en-29-oic acid manufacturer & supplier

Chemical Name:(5ξ,18α)-3,22-Dihydroxyolean-12-en-29-oic acid

CAS.NO:808769-54-2

Synonyms:(5ξ,18α)-3,22-Dihydroxyolean-12-en-29-oic acid;Olean-12-en-29-oic acid, 3,22-dihydroxy-, (5ξ,18α)-

Molecular Formula:C₃₀H₄₈O₄

Molecular Weight:472.700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:584.1±50.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.568

PSA:77.76000

Exact Mass:472.355255

LogP:7.32

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (5ξ,18α)-3,22-Dihydroxyolean-12-en-29-oic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Olean-12-en-29-oic acid, 3,22-dihydroxy-, (5ξ,18α)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Olean-12-en-29-oic acid, 3,22-dihydroxy-, (5ξ,18α)- Use and application,(5ξ,18α)-3,22-Dihydroxyolean-12-en-29-oic acid technical grade,usp/ep/jp grade.

Related News: Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added. (5ξ,18α)-3,22-Dihydroxyolean-12-en-29-oic acid manufacturer Because API companies usually adopt a different synthetic route from the original research company, compared with the drug itself, the impurities contained in the generic drug API have not been verified by the original drug for many years of use and require more careful testing and control. (5ξ,18α)-3,22-Dihydroxyolean-12-en-29-oic acid supplier He pointed out that Taiwan had 10 confirmed cases, versus more than 14,000 in mainland China. (5ξ,18α)-3,22-Dihydroxyolean-12-en-29-oic acid vendor Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease. (5ξ,18α)-3,22-Dihydroxyolean-12-en-29-oic acid factory At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.